Breast Cancer Rapid Recommendation Update on Capivasertib-Fulvestrant

• March 26, 2024
• Legislative Updates

On February 6, a rapid recommendation update on Capivasertib-Fulvestrant was published.
The rapid update has implications for two guidelines: Endocrine Treatment and Targeted
Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancers and Biomarkers for
Systemic Therapy in Metastatic Breast Cancer.